Michael Howell - HUTCHMED DRC Independent Non-Executive Director

HCM Stock  USD 18.16  0.83  4.37%   

Director

Mr. Michael W. D. Howell is an Independent Nonexecutive Director of Hutchison China MediTech Limited since 2006. Mr Howell was an Independent Nonexecutive Director since 2006. He is also Chairman of the Audit Committee and a member of the Remuneration Committee of the Company. From 2002 to 2006, Mr Howell was chief executive of Transport Initiatives Edinburgh Ltd., a publicsector company responsible for major transportation projects in Scotland, including a new tram system for Edinburgh. From 1998 to 2002, he was executive chairman of FPT Group Limited, a global distribution company. Mr Howells prior career was in manufacturing, and transportation services where, after beginning his career in the UK motor industry, he went on to hold senior positions at Cummins Engine and General Electric in the USA and Europe, and Railtrack Group plc in the UK. Mr Howell holds directorships in other private and public companies in the UK and USA. Mr Howell attended Trinity College, Cambridge receiving his Masters degree in EngineeringEconomics from Cambridge University, followed by MBAs from INSEAD and Harvard University . since 2006.
Age 67
Tenure 18 years
Professional MarksMBA
Address Cheung Kong Center, Hong Kong, Hong Kong
Phone852 2121 8200
Webhttps://www.hutch-med.com

HUTCHMED DRC Management Efficiency

As of the 29th of April 2024, Return On Tangible Assets is likely to grow to 0.08. Also, Return On Capital Employed is likely to grow to 0.02. At this time, HUTCHMED DRC's Return On Assets are very stable compared to the past year. HUTCHMED DRC's management efficiency ratios could be used to measure how well HUTCHMED DRC manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 86.13 M in debt. HUTCHMED DRC has a current ratio of 3.12, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist HUTCHMED DRC until it has trouble settling it off, either with new capital or with free cash flow. So, HUTCHMED DRC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like HUTCHMED DRC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for HUTCHMED to invest in growth at high rates of return. When we think about HUTCHMED DRC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Sondra Barbour3M Company
55
Amy Hood3M Company
49
Carol BartzCisco Systems
68
Thomas MayBank of America
73
Margaret WhitmanProcter Gamble
64
Pamela CraigWalmart
60
Patricia WoertzProcter Gamble
67
Debra ReedCaterpillar
61
Dambisa MoyoChevron Corp
52
Randall StephensonWalmart
60
Ronald SugarChevron Corp
72
Aida AlvarezWalmart
65
Roger StoneMcDonalds
79
Linda WolfWalmart
66
John ChevalierProcter Gamble
N/A
John HennessyCisco Systems
64
James UmplebyChevron Corp
60
Thomas Brown3M Company
65
Susan BiesBank of America
74
Carl BassHP Inc
58
Rajiv GuptaHP Inc
69
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchmed China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2110 people. HUTCHMED DRC (HCM) is traded on NASDAQ Exchange in USA. It is located in Cheung Kong Center, Hong Kong, Hong Kong and employs 1,988 people. HUTCHMED DRC is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

HUTCHMED DRC Leadership Team

Elected by the shareholders, the HUTCHMED DRC's board of directors comprises two types of representatives: HUTCHMED DRC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED DRC's management team and ensure that shareholders' interests are well served. HUTCHMED DRC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED DRC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eishi Fukumoto, Executive Officer, Chief Director of Research
Tetsuo Katsurayama, Executive Officer, Chief Director of Finance
Genroku Sugiyama, Executive Officer, Director of India Business
Shigeru Endo, Non-Executive Director
Selina Zhang, Senior Resources
Graeme Jack, Independent Non-Executive Director
Masato Tamaki, Executive Officer, CIO, Chief Director of IT Promotion
Koji Sumioka, Executive Officer, Director of Japan Business and Presidentident of Subsidiary
Simon To, Executive Chairman of the Board
Hong Chen, Senior China
Kenji Ohta, Executive Officer, Deputy Chief Director of Sales, Chief Director of Life Cycle Support Business
Paul Carter, Senior Independent Non-Executive Director
Edith Shih, Company Secretary, Non-Executive Director
Yasushi Ochiai, Managing Executive Officer, Chief Director of Sales
Tsutomu Mizutani, Senior Managing Executive Officer, Director of China Business, Director
Takashi Kawamura, Independent Chairman of the Board of Directors
BSE CS, Company Director
Toshihiro Ohno, Executive Officer, Chief Director of Development, Chief Director of PDI
Osamu Okada, Director
ACGI BSc, Ex Chairman
Yukio Arima, Senior Managing Executive Officer, Chief Director of Strategy Planning, Chief Director of Business Administration, Director
Chig Cheng, CFO, Executive Director
Mitsuhiro Tabei, Managing Executive Officer, Chief Director of Marketing, Director
CA BEc, CFO Director
CS CGP, Company Director
Christian Salbaing, Non-Executive Director
Christian Hogg, CEO, Executive Director
Weiguo Su, Executive Director
Karen Atkin, Executive COO
Hisashi Hasegawa, Executive Officer, Chief Human Resource Officer, Chief Director of Human Resources
Kotaro Hirano, Executive Officer, Chief Director of Business Administration
Hiroshi Tokushige, Executive Vice President Representative Executive Officer, Chief Director of Export Management, Leader of C Project, Director
Christopher Nash, Senior Independent Non-Executive Director
Akihiko Hiraoka, Managing Executive Officer, Deputy Chief Director of China Business, General Manager of Subsidiary
Takayoshi Ikeda, Executive Officer, Deputy Chief Director of China Business, General Manager of Subsidiary
Shigeru Azuhata, Independent Director
Kin MBA, Senior Communications
Michifumi Tabuchi, Executive Officer, Director of China Business, General Manager of Subsidiary
Takuro Sato, Director of Legal Affairs
Charles Nixon, Group Counsel
Qingmei Wang, Senior Alliances
Karen Ferrante, Non-Executive Independent Director
Yuichi Tsujimoto, Executive President Representative Executive Officer, Director
Shu Mok, Non-Executive Independent Director
Michael Howell, Independent Non-Executive Director
Christopher Huang, Independent Non-Executive Director
David Ng, Head Strategies
Dan Eldar, Non-Executive Director
Tadashi Motoi, Executive Officer, Deputy Chief Director of Asian & Oceanian Business and Presidentident of Subsidiary
Hideto Mitamura, Independent Director
Weiguo BSc, Chief CEO
Morio Sumiya, Executive Officer, Director of Europe & Middle East Business and Presidentident of Subsidiary

HUTCHMED Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HUTCHMED DRC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards HUTCHMED DRC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, HUTCHMED DRC's short interest history, or implied volatility extrapolated from HUTCHMED DRC options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether HUTCHMED DRC is a strong investment it is important to analyze HUTCHMED DRC's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact HUTCHMED DRC's future performance. For an informed investment choice regarding HUTCHMED Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HUTCHMED DRC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.
Note that the HUTCHMED DRC information on this page should be used as a complementary analysis to other HUTCHMED DRC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for HUTCHMED Stock analysis

When running HUTCHMED DRC's price analysis, check to measure HUTCHMED DRC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HUTCHMED DRC is operating at the current time. Most of HUTCHMED DRC's value examination focuses on studying past and present price action to predict the probability of HUTCHMED DRC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HUTCHMED DRC's price. Additionally, you may evaluate how the addition of HUTCHMED DRC to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Fundamental Analysis
View fundamental data based on most recent published financial statements
Is HUTCHMED DRC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HUTCHMED DRC. If investors know HUTCHMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HUTCHMED DRC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.6
Revenue Per Share
4.93
Quarterly Revenue Growth
0.36
Return On Assets
0.01
Return On Equity
0.1465
The market value of HUTCHMED DRC is measured differently than its book value, which is the value of HUTCHMED that is recorded on the company's balance sheet. Investors also form their own opinion of HUTCHMED DRC's value that differs from its market value or its book value, called intrinsic value, which is HUTCHMED DRC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HUTCHMED DRC's market value can be influenced by many factors that don't directly affect HUTCHMED DRC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HUTCHMED DRC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.